CA3205058C - Conjugate of immune-stimulating il-2 analog and preparation method thereof - Google Patents

Conjugate of immune-stimulating il-2 analog and preparation method thereof Download PDF

Info

Publication number
CA3205058C
CA3205058C CA3205058A CA3205058A CA3205058C CA 3205058 C CA3205058 C CA 3205058C CA 3205058 A CA3205058 A CA 3205058A CA 3205058 A CA3205058 A CA 3205058A CA 3205058 C CA3205058 C CA 3205058C
Authority
CA
Canada
Prior art keywords
interleukin
analog
amino acids
amino acid
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3205058A
Other languages
English (en)
French (fr)
Other versions
CA3205058A1 (en
Inventor
Yong Ho Heo
Euh Lim Oh
Da Hyeon Park
Jin Young Kim
Jun Sub Park
Yu Yon Kim
A Ram Lee
Sang Yun Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CA3205058A1 publication Critical patent/CA3205058A1/en
Application granted granted Critical
Publication of CA3205058C publication Critical patent/CA3205058C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3205058A 2021-03-31 2022-03-31 Conjugate of immune-stimulating il-2 analog and preparation method thereof Active CA3205058C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210042305 2021-03-31
KR10-2021-0042305 2021-03-31
PCT/KR2022/004620 WO2022211537A1 (ko) 2021-03-31 2022-03-31 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
CA3205058A1 CA3205058A1 (en) 2022-10-26
CA3205058C true CA3205058C (en) 2024-04-09

Family

ID=83459706

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3205058A Active CA3205058C (en) 2021-03-31 2022-03-31 Conjugate of immune-stimulating il-2 analog and preparation method thereof

Country Status (15)

Country Link
US (1) US12599675B2 (enExample)
EP (1) EP4316528A4 (enExample)
JP (1) JP2024512418A (enExample)
KR (2) KR102680146B1 (enExample)
CN (1) CN116916969A (enExample)
AR (1) AR125263A1 (enExample)
AU (1) AU2022209248B2 (enExample)
BR (1) BR112023018530A2 (enExample)
CA (1) CA3205058C (enExample)
CL (1) CL2023002504A1 (enExample)
IL (1) IL304365B2 (enExample)
MX (1) MX2023010926A (enExample)
PE (1) PE20250672A1 (enExample)
WO (1) WO2022211537A1 (enExample)
ZA (1) ZA202307219B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4185605A4 (en) * 2020-07-09 2024-07-17 Eutilex Co., Ltd. IL-2 VARIANTS
WO2024136575A1 (ko) 2022-12-23 2024-06-27 한미약품 주식회사 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제
TW202502372A (zh) * 2023-03-07 2025-01-16 南韓商韓美藥品股份有限公司 包含ｉｌ－２類似物或其接合物之用於預防或治療癌症之醫藥組成物
IL322698A (en) * 2023-03-07 2025-10-01 Hanmi Pharmaceutical Co Ltd Combination therapy containing interleukin 2 analogs or conjugates and immune checkpoint inhibitors for the prevention or treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
KR100507796B1 (ko) * 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EP3834838A1 (en) * 2014-02-21 2021-06-16 Nektar Therapeutics (India) Pvt. Ltd. Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
WO2016014428A2 (en) * 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3943101A1 (en) 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
EP3341025A4 (en) * 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX BY USING A SPECIFIC ROLE OF AN IMMUNOMOBILIN FRAGMENT FOR LINKING
CN115073581A (zh) * 2016-05-04 2022-09-20 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
KR102050463B1 (ko) * 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
SG11201903882VA (en) * 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
PH12020550661A1 (en) * 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
CN119504973A (zh) * 2018-03-28 2025-02-25 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
JP7550745B2 (ja) 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
US12269855B2 (en) * 2018-09-21 2025-04-08 Innovent Biologics (Suzhou) Co., Ltd. Interleukin-2 and use thereof
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
CA3147677A1 (en) * 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists

Also Published As

Publication number Publication date
AU2022209248A1 (en) 2022-10-20
CL2023002504A1 (es) 2024-01-26
MX2023010926A (es) 2023-09-27
PE20250672A1 (es) 2025-03-04
IL304365B1 (en) 2024-12-01
US20240009317A1 (en) 2024-01-11
BR112023018530A2 (pt) 2023-10-10
EP4316528A1 (en) 2024-02-07
AR125263A1 (es) 2023-06-28
ZA202307219B (en) 2024-10-30
KR20240099117A (ko) 2024-06-28
US12599675B2 (en) 2026-04-14
KR20220136285A (ko) 2022-10-07
KR102680146B1 (ko) 2024-07-04
AU2022209248B2 (en) 2023-06-29
CN116916969A (zh) 2023-10-20
JP2024512418A (ja) 2024-03-19
CA3205058A1 (en) 2022-10-26
WO2022211537A1 (ko) 2022-10-06
IL304365B2 (en) 2025-04-01
EP4316528A4 (en) 2026-03-11
IL304365A (en) 2023-09-01
TW202304521A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
US12599675B2 (en) Conjugate of immune-stimulating il-2 analog and preparation method thereof
KR102946368B1 (ko) 신규한 면역 활성 인터루킨 2 아날로그
CN111944036A (zh) 一种增殖免疫细胞的突变体蛋白
KR20220092442A (ko) 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
TWI922649B (zh) 免疫刺激il-2類似物的新穎接合物及其製備方法
HK40100172A (en) Novel immunoactive interleukin 2 analog conjugate and method for preparing same
EP4678180A1 (en) Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof
EP4678181A1 (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
EA049515B1 (ru) Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения
HK40131569A (en) Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof
KR20260065576A (ko) 암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 ctla-4 길항제의 병용 요법
CA3282636A1 (en) Pharmaceutical composition for preventing or treating cancer including interleukin 2 analog or conjugate thereof
HK40130618A (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
CA3282626A1 (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
TWI922560B (zh) 新穎之三重升糖素/ｇｌｐ-１/ｇｉｐ受體促效劑及其用途
HK40079776A (en) Novel immunoactive interleukin 2 analog
KR20240102886A (ko) 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230713

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223